Roche's Fenebrutinib MS Results Test Valuation And Growth Expectations [Yahoo! Finance]
ROCHE HOLDING LTD S/ADR (RHHBY)
NASDAQ:AMEX Investor Relations:
roche.com/investors.htm
Company Research
Source: Yahoo! Finance
Get insights on thousands of stocks from the global community of over 7 million individual investors at Simply Wall St. Roche Holding (SWX:ROG) reported that its investigational MS treatment fenebrutinib met key goals in pivotal Phase III trials. The data show significant reductions in relapse rates and improvements across several clinical endpoints in both relapsing and primary progressive MS. Roche plans to use the Phase III results to support regulatory submissions for fenebrutinib as a potential high efficacy oral therapy. For investors watching Roche Holding at a share price of CHF362.9, fenebrutinib arrives against a backdrop of strong multi year returns. The stock is up 11.5% year to date, 23.9% over 1 year, 49.6% over 3 years and 41.3% over 5 years. This highlights how closely the market is tracking the company's late stage pipeline. The latest MS data could become an important reference point for how investors think about Roche's future earnings mix and research fo
Show less
Read more
Impact Snapshot
Event Time:
RHHBY
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
RHHBY alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
RHHBY alerts
High impacting ROCHE HOLDING LTD S/ADR news events
Weekly update
A roundup of the hottest topics
RHHBY
News
- Lineage Cell Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update [Yahoo! Finance]Yahoo! Finance
- Genentech Announces Positive Phase II Results for Petrelintide, an Amylin Analog Developed for People Living With Overweight and Obesity [Yahoo! Finance]Yahoo! Finance
- Genentech Announces Positive Phase II Results for Petrelintide, an Amylin Analog Developed for People Living With Overweight and ObesityBusiness Wire
- Is Roche Holding (SWX:ROG) Still Attractively Priced After Strong Three Year Share Gains? [Yahoo! Finance]Yahoo! Finance
- Roche announces $481m investment in South Korean biotech sector [Yahoo! Finance]Yahoo! Finance